$JSPR

Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 23, 2026, Herb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer,

Jasper Therapeutics (JSPR) appointed Lisa Pitt and Shiguang Liu to key regulatory and clinical roles. The company reported a Q2 2026 net loss of $2.76M and has $7.3M in cash. It plans FDA meetings for KP-104 and Briquilimab in 2027. JSPR stock is up 5.24% in after-hours trading.

Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 - Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 21, 2026, Jasper Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, base

Jasper Therapeutics (NASDAQ:JSPR) reported Q2 2026 adjusted loss of $0.10 per share, better than the $0.28 consensus, and a net loss of $2.8 million. Shares fell 4.24% pre-market. In July, Jasper completed an all-stock acquisition of Kira Pharmaceuticals and a $132 million private placement, extending its funding runway into 2H 2028. Pipeline updates include KP-104 Phase 2 interim data in Q4 2026 and briquilimab and KP-701 milestones in early 2027.

Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders

Jasper Therapeutics (JSPR) reported Q2 2026 results and a corporate update after completing its all-stock acquisition of Kira Pharmaceuticals on July 16, 2026. The company raised about $132M via a private placement of non-voting convertible preferred stock. Cash was $7.3M at June 30. Net loss was $2.8M. Pipeline updates include KP-104, briquilimab, and KP-701.

Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders . On July 31, 2026, Jasper Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, a total of 21,121,396 shares of the Company’s voting common sto

Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals, forming a combined Nasdaq-listed company under ticker JSPR. The deal includes a $132M private placement and a $12M Mirador out-licensing payment on signing, funding operations through H2 2028. Pipeline includes KP-104, briquilimab, and KP-701 with upcoming clinical milestones.

Jasper Therapeutics (NASDAQ:JSPR) closed a deal with Kira and completed a private placement of non-voting convertible preferred stock raising about $132 million gross. The company expects cash to fund operations through 2H 2028. Jasper out-licensed Kira’s KP-301 and KP-402 to Mirador for $12 million upfront plus milestones. JSPR shares rose 20.67% to $0.9250.

Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 ea029822901ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED JULY 16, 2026, BY AND AMONG JASPER THERAPEUTICS, INC., KIRA HOLDCO INC. AND KIRA PHARMACEUTICALS Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: JASPER THERAPEUTICS, INC., a Delaware corporation; KIRA HOLDCO INC.,